AttendMe Owl Logo
AttendMe
Evidence Evolution
UrologyUrology

How This Evidence Evolved

BPH Surgical Options

From TURP to Minimally Invasive Procedures

33.2

Timeline

Signal

Early observations and pilot data that first suggested a new direction

Clinical studies have assessed transurethral resection of the prostate (TURP) complications and compared it with newer procedures. In a 1989 cooperative study of 3,885 TURP patients at 13 institutions, mortality was 0.2% and immediate postoperative morbidity 18%; morbidity was higher with resection time over 90 minutes, gland size over 45 g, acute urinary retention and age over 80 years, and 77% of patients had significant pre-existing medical problems. In the later WATER trial, 36% of sexually active men had anejaculation after TURP. These reports assess different complications in different treatment eras.
Proof

Landmark RCTs and pivotal trials that established the evidence base

Holmium laser enucleation of the prostate (HoLEP) emerged as a challenger to TURP across prostate sizes. In a randomized trial of 200 men with prostates under 100 cc, postvoid residual volume at three years was 8.4 versus 20.2 mL with HoLEP versus TURP (P=0.012); at 3 years, AUA symptom scores (2.7 vs 3.3, p=0.17) and reoperation rates (7.2% vs 6.6%, p=1.0) were similar. For prostates over 100 g, a 120-patient randomized trial of HoLEP versus open prostatectomy found comparable outcomes at five years among 74 assessed patients, with 46 lost or excluded (mean AUA symptom score 3.0 in both groups; reoperation 5% vs 6.7%, p=1.0). The 2010 Ahyai meta-analysis (23 RCTs, 2245 patients) found statistically comparable efficacy and overall morbidity for HoLEP and other transurethral procedures versus contemporary TURP.
Extension

Follow-up studies, subgroup analyses, and real-world validation

A wave of minimally invasive surgical therapies (MISTs) emerged targeting the gap between medical therapy and traditional surgery, specifically for men wanting symptom relief while preserving sexual function. In the Rezum pivotal trial (197 men), water vapor therapy reduced IPSS by 11.2 vs 4.3 points with sham at 3 months (p<0.0001), with a fall of 50% or more at 3, 6 and 12 months and no de novo erectile dysfunction. In the WATER trial (181 patients), Aquablation was noninferior to TURP for symptom relief at 6 months, with less anejaculation (10% vs 36%, p=0.0003); in WATER II (101 men, 80-150 mL prostates), mean IPSS fell from 23.2 to 6.7 at 3 months.
Now

Current standard of care and ongoing research directions

BPH procedures have been compared in distinct trials. In prostates under 100 cc, HoLEP and TURP had similar 3-year symptom scores and reoperation rates (7.2% vs 6.6%). For prostates over 100 g, HoLEP and open prostatectomy had similar 5-year outcomes among 74 assessed patients; 46 were lost or excluded. WATER found Aquablation noninferior to TURP for 6-month symptom improvement, with anejaculation in 10% versus 36% of sexually active men. L.I.F.T. and Rezum trials compared selected men with sham at 3 months and followed treated men to 12 months. These studies do not establish the lowest retreatment rate across all techniques. What are the longer-term trade-offs, the role of robotic simple prostatectomy in very large glands and the value of imaging-based procedure selection?

Landmark Trials in This Story

Mebust 19891989

Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients.

Mortality and immediate postoperative morbidity after TURP (3,885 patients, 13 institutions): 0.2% and 18%

J UrolRetrospective cooperative study of 13 participating institutionsN=3,885
Ahyai 20102010

Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement

Functional outcomes and treatment-related adverse events

Eur UrolMeta-analysis
Ahyai 2007 (HoLEP vs TURP)2007

Holmium laser enucleation versus transurethral resection of the prostate: 3-year follow-up results of a randomized clinical trial.

AUA symptom score at 3 years: HoLEP 2.7 vs TURP 3.3 (p=0.17); Qmax 29.0 vs 27.5 ml/s (p=0.41); reoperation 7.2% vs 6.6% (p=1.0)

Eur UrolRandomized trial in prostates under 100 cc: 3-year follow-upN=200
Kuntz 2008 (HoLEP vs OP)2008

Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial.

AUA symptom score at 5 years: HoLEP 3.0 vs open prostatectomy 3.0 (p=0.98); Qmax 24.4 ml/s in both (p=0.97); reoperation 5% vs 6.7% (p=1.0)

Eur UrolRandomised clinical trial, prostates greater than 100 g, 5-year follow-upN=120
L.I.F.T.2013Landmark

The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study

AUASI reduction at 3 months: urethral lift 11.1 vs sham 5.9 points (p=0.003)

J UrolRCTN=206
WATER2018Landmark

WATER: A Double-Blind, Randomized, Controlled Trial of Aquablation&#xae; vs Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia

IPSS reduction at 6 months: Aquablation vs TURP (noninferior, p<0.0001); Clavien-Dindo safety end point 26% vs 42% (p=0.0149)

J UrolRCTN=181
Rezum Pivotal2016

Minimally Invasive Prostate Convective Water Vapor Energy Ablation: A Multicenter, Randomized, Controlled Study for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

IPSS reduction at 3 months: Rezum 11.2 vs sham 4.3 points (p<0.0001)

J UrolRCTN=197
WATER II2019

Aquablation for benign prostatic hyperplasia in large prostates (80-150 mL): 6-month results from the WATER II trial.

IPSS at 3 months: 23.2±6.3 at baseline vs 6.7±5.1 (P<0.001); Clavien-Dindo grade 2 or higher or persistent grade 1 events at 3 months 45.5% (goal <65%, P<0.001)

BJU IntProspective multicentre study (16 centres, Canada and USA), prostates 80-150 mLN=101

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Frequently Asked Questions

How do surgical options for BPH compare with TURP?+
HoLEP (holmium laser enucleation) has randomized evidence across prostate sizes. In a 200-patient trial (prostates under 100 cc), HoLEP had lower postvoid residual volume at three years (8.4 vs 20.2 mL, P=0.012), while reoperation rates were similar (7.2% vs 6.6%, p=1.0). For prostates over 100 g, 74 of 120 randomized patients were assessed at 5 years; 46 were lost or excluded. HoLEP versus open prostatectomy reoperation was 5% versus 6.7% (p=1.0). A 2010 meta-analysis of 23 RCTs found statistically comparable efficacy and overall morbidity for HoLEP and other transurethral procedures versus contemporary TURP. The choice depends on prostate size, surgeon expertise, and available equipment.
Which BPH procedures preserve ejaculatory function?+
In the Rezum pivotal trial no de novo erectile dysfunction was reported, and the authors concluded that Rezum preserves erectile and ejaculatory function. In the WATER trial, among sexually active men, anejaculation occurred in 10% after Aquablation vs 36% after TURP (p=0.0003).
What are the limitations of UroLift and Rezum?+
In the Rezum pivotal trial, IPSS fell by 11.2 vs 4.3 points with sham at 3 months (p<0.0001), and Rezum can treat the median lobe.
What is Aquablation and how does it differ from other BPH treatments?+
Aquablation was evaluated against TURP in WATER and in larger prostates in the prospective WATER II study. In the WATER trial (181 patients), it was noninferior to TURP for IPSS reduction at 6 months, with shorter resection time (4 vs 27 minutes, p<0.0001) and less anejaculation among sexually active men (10% vs 36%, p=0.0003). In WATER II (101 men with 80-150 mL prostates), mean IPSS improved from 23.2 to 6.7 at 3 months (P<0.001) and mean hospital stay was 1.6 days.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026